Preclinical Evaluation Of New Antifibrotics In IPF Rodent Models

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease characterized by scar tissue formation, which leads to decreased lung function. With limited treatments available that only slow disease progression, there is a critical need for the development and evaluation of novel therapeutics for IPF. Pulmonary fibrosis animal models play a vital role in preclinical drug development.

Aragen specializes in clinically relevant models, including rodent, ex vivo, and in vitro systems, to support drug discovery efforts for IPF. In collaboration with clients and partners, our experts select the most suitable preclinical model to enhance your drug development pipeline for pulmonary fibrosis.